339 related articles for article (PubMed ID: 19754386)
61. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808
[TBL] [Abstract][Full Text] [Related]
62. P2X7 receptor activation in rat brain cultured astrocytes increases the biosynthetic release of cysteinyl leukotrienes.
Ballerini P; Ciccarelli R; Caciagli F; Rathbone MP; Werstiuk ES; Traversa U; Buccella S; Giuliani P; Jang S; Nargi E; Visini D; Santavenere C; Di Iorio P
Int J Immunopathol Pharmacol; 2005; 18(3):417-30. PubMed ID: 16164825
[TBL] [Abstract][Full Text] [Related]
63. Genetics and pharmacogenetics of the leukotriene pathway.
Tantisira KG; Drazen JM
J Allergy Clin Immunol; 2009 Sep; 124(3):422-7. PubMed ID: 19665766
[TBL] [Abstract][Full Text] [Related]
64. Design, Synthesis and Cellular Characterization of a Dual Inhibitor of 5-Lipoxygenase and Soluble Epoxide Hydrolase.
Meirer K; Glatzel D; Kretschmer S; Wittmann SK; Hartmann M; Blöcher R; Angioni C; Geisslinger G; Steinhilber D; Hofmann B; Fürst R; Proschak E
Molecules; 2016 Dec; 22(1):. PubMed ID: 28036068
[TBL] [Abstract][Full Text] [Related]
65. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries.
Allen S; Dashwood M; Morrison K; Yacoub M
Circulation; 1998 Jun; 97(24):2406-13. PubMed ID: 9641692
[TBL] [Abstract][Full Text] [Related]
66. Regulation of leukotriene biosynthesis.
Ford-Hutchinson AW
Cancer Metastasis Rev; 1994 Dec; 13(3-4):257-67. PubMed ID: 7712588
[TBL] [Abstract][Full Text] [Related]
67. Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism.
Harizi H; Juzan M; Moreau JF; Gualde N
J Immunol; 2003 Jan; 170(1):139-46. PubMed ID: 12496393
[TBL] [Abstract][Full Text] [Related]
68. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Knab LM; Grippo PJ; Bentrem DJ
World J Gastroenterol; 2014 Aug; 20(31):10729-39. PubMed ID: 25152576
[TBL] [Abstract][Full Text] [Related]
69. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice.
Byrum RS; Goulet JL; Snouwaert JN; Griffiths RJ; Koller BH
J Immunol; 1999 Dec; 163(12):6810-9. PubMed ID: 10586081
[TBL] [Abstract][Full Text] [Related]
70. Trauma and hemorrhagic shock activate molecular association of 5-lipoxygenase and 5-lipoxygenase-Activating protein in lung tissue.
Nunns GR; Stringham JR; Gamboni F; Moore EE; Fragoso M; Stettler GR; Silliman CC; Banerjee A
J Surg Res; 2018 Sep; 229():262-270. PubMed ID: 29936999
[TBL] [Abstract][Full Text] [Related]
71. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease.
Montford JR; Bauer C; Dobrinskikh E; Hopp K; Levi M; Weiser-Evans M; Nemenoff R; Furgeson SB
Am J Physiol Renal Physiol; 2019 Apr; 316(4):F732-F742. PubMed ID: 30649890
[TBL] [Abstract][Full Text] [Related]
72. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
[TBL] [Abstract][Full Text] [Related]
73. Leukotriene production profiles and actions in the bovine endometrium during the oestrous cycle.
Korzekwa AJ; Milewski R; Łupicka M; Skarzynski DJ
Reprod Fertil Dev; 2016 Apr; 28(6):682-9. PubMed ID: 25483008
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells.
Titos E; Clària J; Planagumà A; López-Parra M; González-Périz A; Gaya J; Miquel R; Arroyo V; Rodés J
J Leukoc Biol; 2005 Oct; 78(4):871-8. PubMed ID: 16033810
[TBL] [Abstract][Full Text] [Related]
75. Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention.
Chen X; Sood S; Yang CS; Li N; Sun Z
Curr Cancer Drug Targets; 2006 Nov; 6(7):613-22. PubMed ID: 17100567
[TBL] [Abstract][Full Text] [Related]
76. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
Hakonarson H; Thorvaldsson S; Helgadottir A; Gudbjartsson D; Zink F; Andresdottir M; Manolescu A; Arnar DO; Andersen K; Sigurdsson A; Thorgeirsson G; Jonsson A; Agnarsson U; Bjornsdottir H; Gottskalksson G; Einarsson A; Gudmundsdottir H; Adalsteinsdottir AE; Gudmundsson K; Kristjansson K; Hardarson T; Kristinsson A; Topol EJ; Gulcher J; Kong A; Gurney M; Thorgeirsson G; Stefansson K
JAMA; 2005 May; 293(18):2245-56. PubMed ID: 15886380
[TBL] [Abstract][Full Text] [Related]
77. Advances in eicosanoid research, novel therapeutic implications.
Haeggström JZ; Rinaldo-Matthis A; Wheelock CE; Wetterholm A
Biochem Biophys Res Commun; 2010 May; 396(1):135-9. PubMed ID: 20494126
[TBL] [Abstract][Full Text] [Related]
78. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase.
Choi JH; Park HS; Oh HB; Lee JH; Suh YJ; Park CS; Shin HD
Hum Genet; 2004 Mar; 114(4):337-44. PubMed ID: 14749922
[TBL] [Abstract][Full Text] [Related]
79. 5-Lipoxygenase activating protein and leukotriene C4 synthase: therapeutic targets for inhibiting the leukotriene cascade.
Ford-Hutchinson AW
Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():13-21. PubMed ID: 7771328
[No Abstract] [Full Text] [Related]
80. Identification of selective 5-LOX and FLAP inhibitors as novel anti-inflammatory agents by ligand-based virtual screening.
Cerchia C; Küfner L; Werz O; Lavecchia A
Eur J Med Chem; 2024 Jan; 263():115932. PubMed ID: 37976708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
